enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Apixaban - Wikipedia

   en.wikipedia.org/wiki/Apixaban

   [28] [29] In August 2014, the FDA approved apixaban for the additional indication of the treatment of recurring deep vein thrombosis and pulmonary embolism. [28] [30] During its development the drug was known as BMS-562247-01. [31] By late 2019, sales of the product by BMS accounted for thirty percent of their quarterly revenue. [32]

3. Direct factor Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

   The risk of bleeding is increased if used at the same time as other blood thinning drugs such as nonsteroidal anti-inflammatory drugs, antiplatelet drugs and heparin. [2] The blood thinning effects can be reduced if used at the same time as rifampicin and phenytoin , and increased with fluconazole .

4. ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A ...

   www.aol.com/news/2012-12-08-eliquis-apixaban...

   AMPLIFY-EXT (Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY-EXTended Treatment), a randomized, double-blind, multicenter trial ...

5. Discovery and development of direct Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Discovery_and_development...

   Four drugs from the class of direct Xa inhibitors are marketed worldwide. Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. [1] The second one was apixaban (Eliquis), approved in Europe in 2011 [2] and in the United States in 2012. [3]

6. FDA Accepts Eliquis® (apixaban) Supplemental New Drug ... - AOL

   www.aol.com/2013/07/11/fda-accepts-eliquis...

   FDA Accepts Eliquis ® (apixaban) Supplemental New Drug Application for Review for Prophylaxis of Deep Vein Thrombosis Following Hip Or Knee Replacement Surgery PRINCETON, N.J. & NEW YORK ...

7. U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the ... - AOL

   www.aol.com/news/2013-01-02-us-fda-approves...

   U.S. FDA Approves ELIQUIS ® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation ELIQUIS Demonstrated Superior Risk Reductions Versus ...